Astrogliosis as a therapeutic target for neurodegenerative diseases

Neuroscience Letters

Volumn 565, Issue , 2014, Pages 59-64

  Colangelo, Anna Maria ^a   Alberghina, Lilia ^a   Papa, Michele ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Brain homeostasis; Neuroprotection; Neurotrophins; Reactive astrogliosis; Systems biology

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINOBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; AMINO ACID TRANSPORTER; DEXTRO SERINE; GLUTAMIC ACID; INTERLEUKIN 6; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RILUZOLE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; VIMENTIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTOSIS; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN ISCHEMIA; BRAIN METABOLISM; CELL FUNCTION; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; MEDICATION THERAPY MANAGEMENT; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPINAL CORD INJURY;

BRAIN HOMEOSTASIS; NEUROPROTECTION; NEUROTROPHINS; REACTIVE ASTROGLIOSIS; SYSTEMS BIOLOGY;

ANIMALS; ASTROCYTES; BRAIN; DRUG DISCOVERY; GLIOSIS; GLUTAMIC ACID; HUMANS; INFLAMMATION; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION; SYNAPSES; SYSTEMS BIOLOGY;

EID: 84897033768     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.01.014     Document Type: Review

References (43)

1. Agulhon C., Sun M.Y., Murphy T., Myers T., Lauderdale K., Fiacco T.A. Calcium signaling and gliotransmission in normal vs. reactive astrocytes. Front. Pharmacol. 2012, 3:139.
2. Alberghina L., Colangelo A.M. The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. BMC Neurosci. 2006, 7(October (Suppl. 1)):S2.
3. Alberghina L., Gaglio D., Moresco R.M., Gilardi M.C., Messa C., Vanoni M. A systems biology road map for the discovery of drugs targeting cancer cell metabolism. Curr. Pharm. Des. 2013, June. (Epub ahead of print).
4. Bae M.K., Kim S.R., Lee H.J., Wee H.J., Yoo M.A., Ock Oh S., Baek S.Y., Kim B.S., Kim J.B., Sik-Yoon, Bae S.K. Aspirin-induced blockade of NF-kappaB activity restrains up-regulation of glial fibrillary acidic protein in human astroglial cells. Biochim. Biophys. Acta 2006, 1763(3):282-289.
5. Bianco M.R., Berbenni M., Amara F., Viggiani S., Fragni M., Galimberti V., Colombo D., Cirillo G., Papa M., Alberghina L., Colangelo A.M. Cross-talk between cell cycle induction and mitochondrial dysfunction during oxidative stress and nerve growth factor withdrawal in differentiated PC12 cells. J. Neurosci. Res. 2011, 89(8):1302-1315.
6. Brambilla R., Persaud T., Hu X., Karmally S., Shestopalov V.I., Dvoriantchikova G., Ivanov D., Nathanson L., Barnum S.R., Bethea J.R. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J. Immunol. 2009, 182(5):2628-2640.
7. Branger J., van den Blink B., Weijer S., Madwed J., Bos C.L., Gupta A., Yong C.L., Polmar S.H., Olszyna D.P., Hack C.E., van Deventer S.J., Peppelenbosch M.P., van der Poll T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 2002, 168(8):4070-4077.
8. Bruno M.A., Clarke P.B., Seltzer A., Quirion R., Burgess K., Cuello A.C., Saragovi H.U. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J. Neurosci. 2004, 24:8009-8018.
9. Carbone M., Duty S., Rattray M. Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem. Int. 2012, 60(1):31-38.
10. Chen H., O'Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 2008, 167(1):90-95.
11. Cirillo G., Cavaliere C., Bianco M.R., De Simone A., Colangelo A.M., Sellitti S., Alberghina L., Papa M. Intrathecal NGF administration reduces reactive astrocytosis and changes neurotrophin receptors expression pattern in a rat model of neuropathic pain. Cell. Mol. Neurobiol. 2010, 30:51-62.
12. Cirillo G., Bianco M.R., Colangelo A.M., Cavaliere C., de Daniele L., Zaccaro L., Alberghina L., Papa M. Reactive astrocytosis-induced perturbation of synaptic homeostasis is restored by nerve growth factor. Neurobiol. Dis. 2011, 41:630-639.
13. Cirillo G., Colangelo A.M., Bianco M.R., Cavaliere C., Zaccaro L., Sarmientos P., Alberghina L., Papa M. BB14, a nerve growth factor (NGF)-like peptide shown to be effective in reducing reactive astrogliosis and restoring synaptic homeostasis in a rat model of peripheral nerve injury. Biotechnol. Adv. 2012, 30(1):223-232.
14. Colangelo A.M., Bianco M.R., Vitagliano L., Cavaliere C., Cirillo G., De Gioia L., Diana D., Colombo D., Redaelli C., Zaccaro L., Morelli G., Papa M., Sarmientos P., Alberghina L., Martegani E. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J. Neurosci. 2008, 28:2698-2709.
15. Colangelo A.M., Cirillo G., Lavitrano M.L., Alberghina L., Papa M. Targeting reactive astrogliosis by novel biotechnological strategies. Biotechnol. Adv. 2012, 30(1):261-271.
16. Côté S., Carmichael P.H., Verreault R., Lindsay J., Lefebvre J., Laurin D. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2012, 8(3):219-226.
17. Cragnolini A.B., Huang Y., Gokina P., Friedman W.J. Nerve growth factor attenuates proliferation of astrocytes via the p75 neurotrophin receptor. Glia 2009, 57:1386-1392.
18. Crespo I., Roomp K., Jurkowski W., Kitano H., del Sol A. Gene regulatory network analysis supports inflammation as a key neurodegeneration process in prion disease. BMC Syst. Biol. 2012, 6:132.
19. Cuello A.C., Bruno M.A. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem. Res. 2007, 32:1041-1045.
20. Domeniconi M., Hempstead B.L., Chao M.V. Pro-NGF secreted by astrocytes promotes motor neuron cell death. Mol. Cell. Neurosci. 2007, 34:271-279.
21. Franke H., Verkhratsky A., Burnstock G., Illes P. Pathophysiology of astroglial purinergic signalling. Purinergic Signal. 2012, 8(3):629-657.
22. Fujita K.A., Ostaszewski M., Matsuoka Y., Ghosh S., Glaab E., Trefois C., Crespo I., Perumal T.M., Jurkowski W., Antony P.M., Diederich N., Buttini M., Kodama A., Satagopam V.P., Eifes S., Del Sol A., Schneider R., Kitano H., Balling R. Integrating pathways of Parkinson's disease in a molecular interaction map. Mol. Neurobiol. 2013, July. (Epub ahead of print).
23. Giralt A., Friedman H.C., Caneda-Ferrón B., Urbán N., Moreno E., Rubio N., Blanco J., Peterson A., Canals J.M., Alberch J. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther. 2010, 17(10):1294-1308.
24. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
25. Lepore A.C., Rauck B., Dejea C., Pardo A.C., Rao M.S., Rothstein J.D., Maragakis N.J. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 2008, 11(11):1294-1301.
26. Lewerenz J., Klein M., Methner A. Cooperative action of glutamate transporters and cystine/glutamate antiporter system Xc-protects from oxidative glutamate toxicity. J. Neurochem. 2006, 98:916-925.
27. Magistretti P.J. Neuron-glia metabolic coupling and plasticity. J. Exp. Biol. 2006, 209:2304-2311.
28. Marcello L., Cavaliere C., Colangelo A.M., Bianco M.R., Cirillo G., Alberghina L., Papa M. Remodelling of supraspinal neuroglial network in neuropathic pain is featured by a reactive gliosis of the nociceptive amygdala. Eur. J. Pain. 2013, 17:799-810.
29. Mayer E.A. Gut feelings: the emerging biology of gut-brain communication. Nat. Rev. Neurosci. 2011, 12(8):453-466.
30. Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, 3:CD001447.
31. Mizuno S., Iijima R., Ogishima S., Kikuchi M., Matsuoka Y., Ghosh S., Miyamoto T., Miyashita A., Kuwano R., Tanaka H. AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease. BMC Syst. Biol. 2012, 6:52.
32. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett. 2001, 310(2-3):117-120.
33. 2+-dependent glutamate release from astrocytes: vesicular glutamate transporters and cytosolic glutamate levels. Glia 2009, 57:1296-1305.
34. Okada S., Nakamura M., Katoh H., Miyao T., Shimazaki T., Ishii K., Yamane J., Yoshimura A., Iwamoto Y., Toyama Y., Okano H. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat. Med. 2006, 12(7):829-834.
35. Parpura V., Heneka M.T., Montana V., Oliet S.H., Schousboe A., Haydon P.G., Stout R.F., Spray D.C., Reichenbach A., Pannicke T., Pekny M., Pekna M., Zorec R., Verkhratsky A. Glial cells in (patho)physiology. J. Neurochem. 2012, 121(1):4-27.
36. Piao C.S., Kim J.B., Han P.L., Lee J.K. Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. J. Neurosci. Res. 2003, 73(4):537-544.
37. Rothstein J.D., Martin L.J., Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 1992, 326(22):1464-1468.
38. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., Kanai Y., Hediger M.A., Wang Y., Schielke J.P., Welty D.F. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
39. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433(7021):73-77.
40. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119(1):7-35.
41. Squitieri F., Orobello S., Cannella M., Martino T., Romanelli P., Giovacchini G., Frati L., Mansi L., Ciarmiello A. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(7):1113-1120.
42. Verkhratsky A., Rodríguez J.J., Steardo L. Astrogliopathology: a central element of neuropsychiatric diseases?. Neuroscientist 2013, December. (Epub ahead of print).
43. Zaccaro M.C., Lee H.B., Pattarawarapan M., Xia Z., Caron A., L'Heureux P.J., Bengio Y., Burgess K., Saragovi H.U. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem. Biol. 2005, 12:1015-1028.